Latest Medical Cannabis News

Page 1 of 2
ECS Botanics has achieved a milestone with direct-to-consumer sales exceeding 60% of total revenue, driven by the launch of innovative sugar-free THC gummies and a strategic distribution partnership.
Ada Torres
Ada Torres
21 Nov 2025
Bioxyne Limited, through its subsidiary Breathe Life Sciences, has inked an exclusive deal to import, manufacture, and distribute Curaleaf’s Que Medical Inhalation Device in Australia, with a nationwide launch set for November 2025.
Ada Torres
Ada Torres
3 Nov 2025
Cann Group Limited (ASX, CAN) launches a $2.5 million Share Purchase Plan offering eligible shareholders discounted shares and attaching options, supporting its recent debt restructure and growth ambitions.
Ada Torres
Ada Torres
30 Oct 2025
Cann Group Limited reported a near break-even net operating cash flow for Q1 FY2026 and achieved its first EBITDA-positive month, setting the stage for a major debt restructure that will significantly reduce its borrowings.
Ada Torres
Ada Torres
29 Oct 2025
Bioxyne Limited has secured import permits and purchase orders worth A$5.1 million for medical cannabis in Germany, signaling strong early traction in a key European market.
Ada Torres
Ada Torres
15 Sept 2025
Bioxyne Limited projects FY2026 revenue between $65 million and $75 million, driven by expansion in Australian medical cannabis and a landmark $5.8 million contract in Germany.
Victor Sage
Victor Sage
29 Aug 2025
Bioxyne Limited delivered a record FY25 with $30.4 million revenue, driven by Australian market growth and new European contracts. The company projects revenue up to $75 million in FY26, fueled by expanded production and international market entries.
Ada Torres
Ada Torres
29 Aug 2025
Bioxyne Limited has reported record revenue and cash flow for FY25, driven by robust growth in the Australian medical cannabis market and strategic advances into Europe and the UK.
Ada Torres
Ada Torres
29 July 2025
Bod Science Limited reports a dramatic reduction in half-year losses alongside revenue growth driven by a strategic shift to THC products. The company remains under a Deed of Company Arrangement with key corporate actions pending shareholder approval.
Ada Torres
Ada Torres
25 July 2025
Bioxyne Limited has upgraded its FY2025 revenue guidance to approximately $28 million, driven by strong domestic performance and significant progress in European and UK markets. The company also advances its psychedelic medicines pipeline, positioning itself for sustained growth.
Ada Torres
Ada Torres
19 June 2025
Bioxyne Limited, through its subsidiary Breathe Life Sciences, has secured a significant supply agreement to enter Germany’s burgeoning medical cannabis market, promising at least A$5.6 million in revenue for FY2026.
Victor Sage
Victor Sage
18 June 2025
Bioxyne Limited has raised its FY2025 revenue guidance to $28 million, driven by explosive growth in Australian pharmaceutical manufacturing and the upcoming commercial production of MDMA capsules. The company is also making strides in expanding its footprint across Europe.
Victor Sage
Victor Sage
12 June 2025